Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CVS Caremark Corporation : U.S. asks CVS about its prescription discount plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2012 | 10:28pm CET

CVS Caremark Corp said it received requests for information about a prescription drug discount program it runs for uninsured or under-insured individuals from both the U.S. government and the Texas Attorney General.

In January, CVS received a subpoena from the U.S. Office of Inspector General requesting information about the company's Health Savings Pass program, CVS said in its 10k filing on Friday.

The company, which runs the CVS pharmacy chain and the CVS Caremark pharmacy benefits management service, said the request was connected to an investigation of possible false or otherwise improper claims for payment involving Health & Human Services programs.

In February, CVS received a civil investigative demand from Texas' Office of the Attorney General. That office requested a copy of information from the OIG subpoena and other information related to prescription drug claims submitted by CVS pharmacies to Texas Medicaid for reimbursement, the company said.

CVS said it would respond to the requests for information and cooperate with both investigations.

CVS markets its Health Savings Pass, which has a $15 annual fee, to people who do not have prescription drug coverage and to those who have limited coverage.

The Health Savings Pass lets patients fill 90-day prescriptions for 400 generic drugs for $11.99. Participants also get discounts such as 10 percent off visits at the CVS in-store health clinic, MinuteClinic and 10 percent off an annual flu shot.

The announcement comes about a month after CVS agreed to pay $5 million to settle charges of inaccurate pricing of some drugs for the elderly and disabled, ending a wide-ranging, multi-year probe into its business practices.

Shares of CVS closed down 28 cents at $44.27, after reaching a new high of $45 earlier in the day.

(Reporting by Jessica Wohl in Chicago; Editing by Richard Chang)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
01/14 CVS HEALTH : Canada Pension Plan Investment Board Has $249,866,000 Position in C..
01/14 CVS HEALTH : targets EpiPen with cheaper, generic version
01/13 CVS HEALTH : unveils generic competitor to EpiPen for one-sixth the price
01/13 CVS HEALTH : More Mylan misery
01/13 CVS HEALTH : Vende CVS versión genérica de Epipen a un sexto de su precio
01/12 CVS HEALTH : generic competitor to EpiPen, sold at a 6th the price
01/12 CVS HEALTH : puts out generic competitor to EpiPen at a 6th the price
01/12 CVS HEALTH : Flu Shots Available at CVS Pharmacy Locations in Washington
01/12 CVS HEALTH : Supporting Those Who Care for Our Aging Population
01/09 CVS HEALTH : Carjacking victim, shot nine times, suing CVS
More news
Sector news : Drug Retailers - NEC
03:03aDJMCKESSON : to Pay $150 Million for Failing to Report 'Suspicious' Drug Orders --..
01:47aDJMCKESSON : to Pay $150 Million for Failing to Report 'Suspicious' Drug Orders
01/11DJWalgreens to Offer FedEx Dropoff and Pickup at Walgreens Locations Nationwide
01/05 U.S. loses bid to overturn AmEx antitrust decision
01/05DJWALGREENS BOOTS CEO : No Plan B for Rite Aid Merger--Update
More sector news : Drug Retailers - NEC
News from SeekingAlpha
01/17 DGI FOR THE DIY : 2016 Portfolio Review
01/17 Impax Laboratories Stock To Rise On New Catalyst
01/16 Portfolio Update - CVS Health Corp. Purchased
01/16 CVS HEALTH : Strong Yield With A Catalyst
01/16 9 Dividend Companies With Lower Share Prices
Advertisement
Financials ($)
Sales 2016 178 057 M
EBIT 2016 10 773 M
Net income 2016 5 672 M
Debt 2016 24 647 M
Yield 2016 1,96%
P/E ratio 2016 16,47
P/E ratio 2017 15,67
EV / Sales 2016 0,64x
EV / Sales 2017 0,61x
Capitalization 89 496 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 88,0 $
Spread / Average Target 4,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP6.35%89 496
WALGREENS BOOTS ALLIAN..1.76%90 908
EXPRESS SCRIPTS HOLDIN..6.35%45 112
MCKESSON CORPORATION5.68%33 558
CARDINAL HEALTH INC4.46%24 062
AMERISOURCEBERGEN CORP..9.98%18 926
More Results